Clinical management of difficult to treat macroprolactinomas

References

• Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.
   PubMed Web of Science ®Google Scholar
• Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–596.
   PubMed Web of Science ®Google Scholar
• Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545–553.
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8:3–6.
   Google Scholar
• Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an international pituitary pathology club proposal. Endocr Relat Cancer. Internet]. 2017 [cited 2019 Jan 21];24:C5–C8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28264912
   PubMed Web of Science ®Google Scholar
• Heaney AP. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3649–3660.
   Web of Science ®Google Scholar
• Abbara A, Clarke SA, Nesbitt A, et al. Interpretation of serum gonadotropin levels in hyperprolactinaemia. Neuroendocrinology. Internet]. 2018 [cited 2019 Jan 7];107:105–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29660734
   PubMed Web of Science ®Google Scholar
• Page-Wilson G, Smith PC, Welt CK. prolactin suppresses GnRH but not TSH secretion. Horm Res Paediatr. Internet]. 2006 [cited 2019 Jan 7];65:31–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16357488
   Google Scholar
• Sonigo C, Bouilly J, Carré N, et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. Internet]. 2012 [cited 2019 Jan 7];122:3791–3795. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23006326
   PubMed Web of Science ®Google Scholar
• Kaiser UB. Hyperprolactinemia and infertility: new insights. J Clin Invest. Internet]. 2012 [cited 2019 Jan 7];122:3467–3468. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23193578
   PubMed Web of Science ®Google Scholar
• Comninos AN, Demetriou L, Wall MB, et al. Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. JCI Insight. Internet]. 2018 [cited 2019 Jan 7];3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30333302
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Porcelli T, Mormando M, et al. Vertebral fractures in males with prolactinoma. Endocrine. Internet]. 2011 [cited 2019 Jan 21];39:288–293. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21479837
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Mancini T, Mormando M, et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. Internet]. 2011 [cited 2019 Jan 21];14:299–306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21301967
   PubMed Web of Science ®Google Scholar
• Tirosh A, Benbassat C, Lifshitz A, et al. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2015;18:108–115.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and treatment of pituitary adenomas. JAMA. 2017;317:516.
   PubMed Web of Science ®Google Scholar
• Tirosh A, Shimon I. Management of macroprolactinomas. Clin Diabetes Endocrinol. 2015;1:5.
   PubMedGoogle Scholar
• Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–763.
   PubMed Web of Science ®Google Scholar
• Cuny T, Barlier A, Feelders R, et al. Medical therapies in pituitary adenomas: current rationale for the use and future perspectives. Ann Endocrinol (Paris). 2015;76:76.
   Web of Science ®Google Scholar
• Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. Internet]. 1985 [cited 2018 Nov 4];60:698–705. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-60-4-698
   PubMed Web of Science ®Google Scholar
• Dallabonzana D, Liuzzi A, Oppizzi G, et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab. 1986;63:1002–1007.
   PubMed Web of Science ®Google Scholar
• Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011;7:267–278.
   PubMed Web of Science ®Google Scholar
• Wong A, Eloy JA, Couldwell WT, et al. Update on prolactinomas. Part 2: treatment and management strategies. J Clin Neurosci. 2015;22:1568–1574.
   PubMed Web of Science ®Google Scholar
• Kissner DG, Jarrett JC. Side effects of bromocriptine. N Engl J Med. Internet]. [cited 2018 Nov 4];302:749–750. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM198003273021313
   PubMed Web of Science ®Google Scholar
• Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. Internet]. 2015 [cited 2018 Nov 4];172:R205–R213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25805896
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. cabergoline comparative study group. N Engl J Med. 1994;331:904–909.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Guerra E, et al. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006;2:200–210.
   PubMedGoogle Scholar
• Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–2522.
   PubMed Web of Science ®Google Scholar
• Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704–1711.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi ML, et al. macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. Internet]. 2000 [cited 2018 Sep 4];85:2247–2252. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10852458
   PubMed Web of Science ®Google Scholar
• Delgrange E, Daems T, Verhelst J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747–752.
   PubMed Web of Science ®Google Scholar
• Delgrange E, Raverot G, Bex M, et al. Giant prolactinomas in women. Eur J Endocrinol. Internet]. 2014;170:31–38. Available from: https://eje.bioscientifica.com/view/journals/eje/170/1/31.xml
   PubMed Web of Science ®Google Scholar
• Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100:1177–1186.
   Web of Science ®Google Scholar
• Raverot G, Jacob M, Jouanneau E, et al. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol (Oxf). Internet]. 2009 [cited 2019 Jan 7];70:588–592. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18673461
   PubMed Web of Science ®Google Scholar
• Netea-Maier RT, van Lindert EJ, Timmers H, et al. Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas. J Endocrinol Invest. Internet]. 2006 [cited 2018 Nov 4];29:1001–1005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17259798
   PubMed Web of Science ®Google Scholar
• Paepegaey A-C, Salenave S, Kamenicky P, et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J Endocr Soc. 2017;1:221–230.
   PubMed Web of Science ®Google Scholar
• Vroonen L, Lancellotti P, Garcia MT, et al. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine. 2017;55:239–245.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. Internet]. 2011 [cited 2018 Nov 5];96:273–288. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21296991
   PubMed Web of Science ®Google Scholar
• Noronha S, Stokes V, Karavitaki N, et al. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine. 2016;51:205–210.
   PubMed Web of Science ®Google Scholar
• Van’t Verlaat JW, Croughs RJ, Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205–502. Clin Endocrinol (Oxf). Internet]. 1990 [cited 2019 Jan 21];33:619–624. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1979262
   PubMed Web of Science ®Google Scholar
• Kvistborg A, Halse J, Bakke S, et al. Long-term treatment of macroprolactinomas with CV 205–502. Acta Endocrinol (Copenh). Internet]. [cited 2019 Jan 21];128:301–307. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8098891
   PubMedGoogle Scholar
• Schultz PN, Ginsberg L, McCutcheon IE, et al. Quinagolide in the management of prolactinoma. Pituitary. 2000;3:239–249.
   PubMedGoogle Scholar
• Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf). 2000;53:53–60.
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. Internet]. 2014 [cited 2018 Nov 4];117:421–428. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24146188
   PubMed Web of Science ®Google Scholar
• Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. Internet]. 2008 [cited 2018 Nov 5];93:4721–4727. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2007-2758
   PubMed Web of Science ®Google Scholar
• Vroonen L, Jaffrain-Rea M-L, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651–662.
   PubMed Web of Science ®Google Scholar
• Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989;69:500–509.
   PubMed Web of Science ®Google Scholar
• Pellegrini I, Costa R, Grisoli F, et al. Abnormal dopamine sensitivity in some human prolactinomas. Horm Res. 1989;31:19–23.
   PubMedGoogle Scholar
• Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314–322.
   PubMed Web of Science ®Google Scholar
• Caccavelli L, Morange-Ramos I, Kordon C, et al. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol. 1996;8:737–746.
   PubMed Web of Science ®Google Scholar
• Shimazu S, Shimatsu A, Yamada S, et al. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2012;166:383–390.
   PubMed Web of Science ®Google Scholar
• Bueno C, Trarbach E, Bronstein M, et al. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment. Pituitary. 2017;20:295–300.
   PubMed Web of Science ®Google Scholar
• Filopanti M, Barbieri AM, Angioni AR, et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J. 2008;8:357–363.
   PubMed Web of Science ®Google Scholar
• Gao H, Wang F, Lan X, et al. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer. 2015;15:15.
   PubMed Web of Science ®Google Scholar
• Cheedipudi S, Puri D, Saleh A, et al. A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene. Nucleic Acids Res. Internet]. 2015 [cited 2018 Nov 4];43:6236–6256. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26040698
   PubMed Web of Science ®Google Scholar
• Recouvreux MV, Camilletti MA, Rifkin DB, et al. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol. 2016;228:R73–R83.
   PubMed Web of Science ®Google Scholar
• Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791.
   PubMed Web of Science ®Google Scholar
• Heldin C-H, Miyazono K, Ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–471.
   PubMed Web of Science ®Google Scholar
• Sarkar DK, Kim KH, Minami S. Transforming growth factor-beta 1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol. 1992;6:1825–1833.
   PubMedGoogle Scholar
• Recouvreux MV, Guida MC, Rifkin DB, et al. Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary. Endocrinology. 2011;152:2722–2730.
   PubMed Web of Science ®Google Scholar
• Li Z, Liu Q, Li C, et al. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas. Mol Cell Endocrinol. 2015;402:64–71.
   PubMed Web of Science ®Google Scholar
• Marini F, Falchetti A, Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. Internet]. 2006 [cited 2018 Nov 5];1:38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17014705
   PubMedGoogle Scholar
• Vergès B, Boureille F, Goudet P, et al. Pituitary disease in men type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): A case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32:534–543.
   PubMed Web of Science ®Google Scholar
• Delemer B. MEN1 and pituitary adenomas. Ann Endocrinol (Paris). 2012;73:59–61.
   PubMed Web of Science ®Google Scholar
• Subasinghe CJ, Somasundaram N, Sivatharshya P, et al. Giant prolactinoma of young onset: a clue to diagnosis of MEN-1 syndrome. Case Rep Endocrinol. Internet]. 2018 [cited 2018 Nov 4];2018:1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30186640
   Google Scholar
• Beckers A, Aaltonen LA, Daly AF, et al. familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. Internet]. 2013 [cited 2018 Nov 21];34:239–277. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23371967
   PubMed Web of Science ®Google Scholar
• Peverelli E, Mantovani G, Vitali E, et al. Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab. 2012;97:967–977.
   PubMed Web of Science ®Google Scholar
• Wang F, Gao H, Li C, et al. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. J Neurooncol. 2014;116:83–88.
   PubMed Web of Science ®Google Scholar
• Huang HY, Zhai W, Tang H, et al. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine. Internet]. 2018 [cited 2019 Jan 20];62:464–469. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30238326
   PubMed Web of Science ®Google Scholar
• Dos Santos Nunes V, El Dib R, Boguszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. Internet]. 2011 [cited 2018 Nov 4];14:259–265. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21221817
   PubMed Web of Science ®Google Scholar
• Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol. Internet]. 1996 [cited 2019 Jan 20];134:454–456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8640297
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. Internet]. 1997 [cited 2019 Jan 21];82:876–883. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9062500
   PubMed Web of Science ®Google Scholar
• Gillam MP, Middler S, Freed DJ, et al. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab. Internet]. [cited 2019 Jan 20];87:4447–4451. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2002-020426
   PubMed Web of Science ®Google Scholar
• Iyer P, Molitch M. positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract. Internet]. 2011 [cited 2019 Jan 20];17:e55–e58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21324816
   PubMedGoogle Scholar
• Kreutzer J, Buslei R, Wallaschofski H, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158:11–18.
   PubMed Web of Science ®Google Scholar
• Shimon I, Sosa E, Mendoza V, et al. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary. 2016;19:429–436. Internet]. Available from: http://link.springer.com/10.1007/s11102-016-0723-4
   PubMed Web of Science ®Google Scholar
• Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. Internet]. 2007 [cited 2019 Jan 7];156:225–231. Available from: https://eje.bioscientifica.com/view/journals/eje/156/2/1560225.xml
   PubMed Web of Science ®Google Scholar
• Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58:662–670.
   PubMed Web of Science ®Google Scholar
• Hamilton DK, Vance ML, Boulos PT, et al. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005;8:53–60.
   PubMedGoogle Scholar
• Dallapiazza RF, Jane JA. Outcomes of endoscopic transsphenoidal pituitary surgery. Endocrinol Metab Clin North Am. 2015;44:105–115.
   PubMed Web of Science ®Google Scholar
• Jan M, Dufour H, Brue T, et al. Prolactinoma surgery. Ann Endocrinol (Paris). 2007;68:118–119.
   PubMed Web of Science ®Google Scholar
• Song Y-J, Chen M-T, Lian W, et al. Surgical treatment for male prolactinoma. Medicine (Baltimore). 2017;96:e5833.
   PubMed Web of Science ®Google Scholar
• Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166:779–786.
   PubMed Web of Science ®Google Scholar
• Donegan D, Atkinson JLD, Jentoft M, et al. Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract. 2017;23:37–45.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Régis J, Dufour H, et al. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010;6:214–223.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Nagai M, Morange I, et al. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab. 2009;94:3400–3407.
   PubMed Web of Science ®Google Scholar
• Pouratian N, Sheehan J, Jagannathan J, et al. gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59:255–266.
   PubMed Web of Science ®Google Scholar
• Ježková J, Hána V, Kršek M, et al. Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol (Oxf). 2009;70:732–741.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Link MJ, Brown PD, et al. gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. Internet]. 2010 [cited 2019 Jan 8];74:147–152. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1878875010002020
   PubMed Web of Science ®Google Scholar
• Cohen-Inbar O, Xu Z, Schlesinger D, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary. 2015;18:820–830.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Brue T. Gamma knife radiosurgery in pituitary adenomas: why, who, and how to treat? Discov Med. 2010;10:107–111.
   PubMed Web of Science ®Google Scholar
• Regis J, Castinetti F. Radiosurgery: a useful first-line treatment of prolactinomas? World Neurosurg. 2010;74:103–104.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. Internet]. 2005 [cited 2018 Nov 6];352:987–996. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758009
   PubMed Web of Science ®Google Scholar
• Zhang J, Stevens MFG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. Internet]. [cited 2019 Jan 22];5:102–114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22122467
   PubMedGoogle Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Internet]. 2005 [cited 2019 Jan 16];352:997–1003. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758010
   PubMed Web of Science ®Google Scholar
• Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7:518–520.
   Web of Science ®Google Scholar
• Raverot G, Sturm N, De Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. J Clin Endocrinol Metab. 2010.
   Web of Science ®Google Scholar
• Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76:769–775.
   PubMed Web of Science ®Google Scholar
• Lasolle H, Cortet C, Castinetti F, et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol. 2017;176:769–777.
   PubMed Web of Science ®Google Scholar
• Philippon M, Morange I, Barrie M, et al. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Ann Endocrinol (Paris). Internet]. 2012 [cited 2018 Nov 7];73:225–229. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22520146
   PubMed Web of Science ®Google Scholar
• Raverot G, Burman P, McCormack A, et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1–G24.
   Web of Science ®Google Scholar
• Fusco A, Gunz G, Jaquet P, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008;158:595–603.
   PubMed Web of Science ®Google Scholar
• Fusco A, Lugli F, Sacco E, et al. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary. 2011;14:351–357.
   PubMed Web of Science ®Google Scholar
• Sosa-Eroza E, Espinosa E, Ramírez-Rentería C, et al. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. Endocrine. Internet]. 2018 [cited 2018 Nov 4];61:343–348. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29948930
   PubMed Web of Science ®Google Scholar
• Cuny T, Mohamed A, Graillon T, et al. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion. Mol Cell Endocrinol. 2012;355:106–113.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–884.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577–1585.
   PubMed Web of Science ®Google Scholar
• Fedele M, De Martino I, Pivonello R, et al. SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. Clin Cancer Res. 2007;13:2738–2744.
   PubMed Web of Science ®Google Scholar
• Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). Internet]. 2018 [cited 2018 Nov 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30318256
   PubMedGoogle Scholar
• Baldari S, Ferraù F, Alafaci C, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. Internet]. 2012 [cited 2018 Nov 9];15 Suppl 1: S57–60. Available from: http://link.springer.com/10.1007/s11102-011-0373-5
   PubMedGoogle Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. Internet]. 2017 [cited 2018 Jul 14];376:125–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28076709
   PubMed Web of Science ®Google Scholar
• Liu X, Liu Y, Gao J, et al. Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas: pilot study. World Neurosurg. 2018;115:94–98.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu Y, Han G, et al. Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. J Cell Mol Med. Internet]. 2018 [cited 2018 Nov 4]; 22:6368–6379. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30334324
   Web of Science ®Google Scholar
• Esparís-Ogando A, Montero JC, Arribas J, et al. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. Internet]. 2016 [cited 2018 Nov 6];22:5887–5898. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27426127
   PubMed Web of Science ®Google Scholar
• Kontogeorgos G, Stefaneanu L, Kovacs K, et al. Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol. 1996;7:63–70.
   Web of Science ®Google Scholar
• Cooper O, Mamelak A, Bannykh S, et al. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014;46:318–327.
   PubMed Web of Science ®Google Scholar
• Cooper O, Vlotides G, Fukuoka H, et al. Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer. 2011;18:R197–R211.
   PubMed Web of Science ®Google Scholar
• Vlotides G, Siegel E, Donangelo I, et al. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 2008;68:6377–6386.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976.
   PubMed Web of Science ®Google Scholar
• Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer. 2009;16:1329–1338.
   Web of Science ®Google Scholar
• Roof AK, Jirawatnotai S, Trudeau T, et al. The balance of PI3K and ERK signaling is dysregulated in prolactinoma and modulated by dopamine. Endocrinology. 2018;159:2421–2434.
   PubMed Web of Science ®Google Scholar
• Chen R, Duan J, Li L, et al. MTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 2017;36:979.
   PubMed Web of Science ®Google Scholar
• Geng X, Ma L, Li Z, et al. Bromocriptine induces autophagy-dependent cell death in pituitary adenomas. World Neurosurg. 2017;100:407–416.
   PubMed Web of Science ®Google Scholar
• Zhang D, Way JS, Zhang X, et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab. Internet]. 2019 [cited 2019 Jan 20]; Available from: https://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2018-02461/5273783
   Google Scholar
• Smith TR, Hulou MM, Huang KT, et al. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci. Internet]. 2015 [cited 2018 Nov 4];22:1785–1791. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26277642
   PubMed Web of Science ®Google Scholar
• Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3:906–913.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Roy P, Sturm N, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. Internet]. 2013 [cited 2019 Mar 9];126:123–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23400299
   PubMed Web of Science ®Google Scholar
• Eroukhmanoff J, Tejedor I, Potorac I, et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol. 2017;176:123–132.
   PubMed Web of Science ®Google Scholar
• Lin AL, Jonsson P, Tabar V, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. Internet]. 2018 [cited 2019 Jan 23];103:3925–3930. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30085142
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574–3579.
   PubMed Web of Science ®Google Scholar
• Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf). 1997;46:409–413.
   PubMed Web of Science ®Google Scholar
• Espinosa E, Sosa E, Mendoza V, et al. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52:652–659.
   PubMed Web of Science ®Google Scholar
• Green AI, Sherlock M, Stewart PM, et al. Extensive experience in the management of macroprolactinomas. Clin Endocrinol (Oxf). 2014;81:85–92.
   PubMed Web of Science ®Google Scholar
• Wu ZR, Zhang Y, Cai L, et al. Long-term clinical outcomes of invasive giant prolactinomas after a mean ten-year followup. Int J Endocrinol. 2016;2016:1–7.
   Google Scholar
• Rohmer V, Freneau E, Morange I, et al. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. club de l’Hypophyse. Ann d Endocrinol. 2000;61:411–417.
   PubMed Web of Science ®Google Scholar